Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, botulinum toxin type A (Botox®) cannot be endorsed for use within NHS Wales for the management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who are not adequately managed with anticholinergics. |
||
|
||
Medicine details |
||
| Medicine name | botulinum toxin type A (Botox®) | |
| Formulation | 50 units, 100 units and 200 units powder for solution for injection | |
| Reference number | 1845 | |
| Indication | Management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who are not adequately managed with anticholinergics |
|
| Company | Allergan Ltd | |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 06/12/2013 | |